Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 22%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics is poised for strong growth in the coming years with sales expected to increase due to strong Q1 results, a rise in new patient starts, and progress on their Mint and Bihormonal pumps. However, there are risks such as potential competition, a recent FDA warning letter, and potential fluctuations in reported events with changes in reporting standards. With a favorable risk-reward profile and plans for FDA approval and launch of their Mint patch pump in 2027, BBNX has the potential to grow significantly.

Bears say

Beta Bionics is a promising commercial-stage medical device company with a strong focus on improving the treatment of diabetes and enhancing the lives of patients. Despite the recent pressure on stock prices, the company has reported strong Q1 results, with increased guidance, new patient additions, and better-than-expected pharmacy adds. Gross margin and sales force expansion are also progressing well, making it an attractive investment opportunity with a target price of $20.

BBNX has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 22% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 9 analysts, BBNX has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.